Sensei Biotherapeutics Inc (SNSE NASDAQ) stock market data APIs
$19.9882
0.9(4.5%)
as of May 18, 2026
Try our APIs with
free plan!
Sensei Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Prev. Close
19.9882
Open
20.8861
High
22.5517
Low
19.9878
52 wk Range
5.26-36.76
Market Cap
27 399 K
Shares Outstanding
1 341 K
EPS
-131.45
Beta
-0.184
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Sensei Biotherapeutics Inc data using free add-ons & libraries
Get Sensei Biotherapeutics Inc Fundamental Data
Sensei Biotherapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -185 506 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Sensei Biotherapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.62
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Sensei Biotherapeutics Inc News
New
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tu...
Sensei Biotherapeutics (SNSE): Best Performing NASDAQ Stocks According to Wall Street Analysts
Sensei Biotherapeutics Inc. (NASDAQ:SNSE) is one of the best performing NASDAQ stocks according to Wall Street analysts. On March 30, Sensei Biotherapeutics shifted its focus following the acquisition...
Most and least shorted small-to-mid-cap stocks
[short sale sign] Gunter_Nezhoda Short interest across small- to mid-cap stocks highlights extreme positioning at both ends, with highly speculative micro-cap names drawing heavy bearish bets, while ...
Sensei Biotherapeutics GAAP EPS of -$16.72
* Sensei Biotherapeutics press release [https://seekingalpha.com/pr/20454976-sensei-biotherapeutics-reports-full-year-2025-financial-results-and-provides-corporate-update] (SNSE [https://seekingalph...
Get Sensei Biotherapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
